


AMENDMENTS TO THE CLAIMS:

Please amend the claims as follows:


Claims 1-28. (Cancelled)

29. (Currently Amended) Compounds having an anti-parasitic, in particular antimalarial, activity characterized in that they correspond to general formula (I)



in which

either X represents a group of formula (II)



where Z is a $-(\text{CH}_2)_m$ group, with $m = 8$ to 21 ,

$n = 0$ or 1

and $\text{Y} = \text{R}_3$,

R_1 and R'_1 , identical to or different from one another, being chosen from H, alkyl, OH, O-alkyl, O-aryl, O-CO-alkyl, O-CO-aryl, OSO_2 -alkyl, OSO_2 -aryl, OSO_2^- heterocycle,

VIAL et al.
Appl. No. 10/521,329
Atty. Ref.: 1721-83
Amendment
December 23, 2008

O-CO-O(or S or NH)-alkyl, O-CO-O(or S or NH)-aryl, PO(O-alkyl or O-aryl)₂, CO-O-CH₂-aryl, cycloalkyl,

R₂ and R'₂, identical to or different from one another, being chosen from H, alkyl, CO-O-CH₂-aryl, CO-O-alkyl, cycloalkyl,

R₃ and R'₃, identical to or different from one another, representing H, alkyl, CO-O-aryl, COO-CH(R)-O-CO-alkyl, PO(O-alkyl or O-aryl or ONa)₂, CO-O-CH(R)-aryl,


R being H or alkyl,

[[or]]and

R₁ and R₂, and/or R'₁ and R'₂, or R₂ and R₃ and/or R'₂ and R'₃, together form a mono heterocycle with the nitrogen atom or atoms to which they are respectively attached, or also,

R₂ and R₃ and/or R'₂ and R'₃ can be the same substituent, double-bonded to the nitrogen, cyclized with, respectively, R₁ or R'₁ in order to form a heterocycle, if appropriate substituted by R_a, which is chosen from H, alkyl, alkyl substituted by 1, 2 or 3 halogen atoms, aryl, CO-O-alkyl (or aryl), -CO-OH, -CO-NH₂, -CN, -CO-NH-alkyl (or aryl), -CO-N-(alkyl)₂, nitrogenated and/or oxygenated -CO-heterocycle, NH(H or alkyl), N(alkyl)₂, nitrogenated and/or oxygenated heterocycle, -O-alkyl (or aryl), -O-CH₂-aryl, CH₂N[H, (H, alkyl), (dialkyl), aryl], nitrogenated and/or oxygenated -CH₂-heterocycle, CH₂-CO-OH,

or $X = R_4$ and Y represents a group of formula (III)



with n and Z as defined above,

R_4 and R'_4 , identical to or different from one another, being chosen from H, alkyl, OH, O-alkyl, O-aryl, O-CO-alkyl, O-CO-aryl, OSO_2 -alkyl, OSO_2 -aryl, OSO_2 -heterocycle, O-CO-O(or S or NH)-alkyl, O-CO-O(or S or NH)-aryl, $\text{PO}(\text{O-alkyl or O-aryl})_2$, CO-O- CH_2 -aryl, cycloalkyl,

R_4 and R'_4 represent an H, alkyl or aryl, which can be substituted by OH, O-alkyl, O-aryl, NH (H or alkyl), nitrogenated or oxygenated heterocycle, and


R_2 and R'_2 , identical to or different from one another, being chosen from H, alkyl, CO-O- CH_2 -aryl, CO-O-alkyl, cycloalkyl, or

R_4 and R_4 and/or R_4 and R'_4 together form a $(\text{CH}_2)_p$ group, p being an integer from 1 to 5, one or several hydrogen atoms being optionally changed for a lower alkyl and R_2 and R'_2 representing H, or R_4 and R_2 and/or R_4 and R'_2 together form a $(\text{CH}_2)_p$ group, one or several H being optionally changed for a lower alkyl, R_4 and R'_4 representing [[H,]] and the pharmacologically acceptable salts of these compounds,


with the proviso that n is not zero when Z is (CH₂)_m and m=10, and both oxadiazoles are substituted by Me(CH₂)₈, and

with the proviso that said compounds are not 1,8-bis [3- (5-amino-1,2,4 triazolyl)-octane; 1,12-Bis(2-amino-3,4,5,6-tetrahydropyrimidyl)dodecane diacetate; 1,12-Bis(2-amino-3,4,5,6-tetrahydropyrimidyl)dodecane dihydroiodide or tetrapyrimidinyl derivatives linked by a group Z=(CH₂)₁₀.

30. (Previously Presented) Compounds according to claim 29, characterized in that they correspond to formula (IV)



31. (Previously Presented) Compounds according to claim 30, characterized in that they correspond to formula (V)



32. (Previously Presented) Compounds according to claim 31, characterized in that R₁, R'₁, R₂, R'₂, R₃ and R'₃ are independent of one another.

33. (Previously Presented) Compounds according to claim 32, characterized in that R_1 and/or R'_1 are as defined above, but do not represent a hydrogen atom, whilst R_3 and/or R'_3 , R_2 and/or R'_2 , represent a hydrogen atom, R_1 , R_2 and R_3 .

34. (Previously Presented) Compounds according to claim 33, characterized in that R_1 and/or R'_1 , and R_2 and/or R'_2 represent a hydrogen atom, whilst R_3 and/or R'_3 are as defined above, but different from a hydrogen atom.


35. (Previously Presented) Compounds according to claim 31, characterized in that

– R_1 and R_2 , and/or R'_1 and R'_2 , or


– R_2 and R_3 , and/or R'_2 and R'_3 , or

– R_1 , R_2 and R_3 and/or R'_1 , R'_2 and R'_3 together form a heterocycle.

36. (Previously Presented) Compounds according to claim 35, characterized in that R_1 and R_2 as well as R'_1 and R'_2 form a heterocycle and correspond to formula (VI)



37. (Previously Presented) Compounds according to claim 35, characterized in that they correspond to formula (VII)




38. (Previously Presented) Compounds according to claim 36, characterized in that formula (VI) R_1 and R_2 and/or R'_1 and R'_2 together form an $-O-CO-$, $O-SO-$, $O-CS$, $S-CO$ or $-S-CS$ group, and R_3 and/or R'_3 represent a hydrogen atom.

39. (Previously Presented) Compounds according to claim 36, characterized in that R_1 and R_2 , and/or R'_1 and R'_2 represent an optionally branched alkylene group and R_3 and/or R'_3 represent $-CO-O$ -alkyl (or aryl), $-CO-O-CH_2$ -aryl, $CO-O-CH(alkyl)-O-CO$ -alkyl, $PO(O$ -alkyl or -aryl) $_2$, alkyl or H.

40. (Currently Amended) Compounds according to claim 37, characterized in that R_1 and/or R'_1 represent a hydrogen atom, and R_2 and R_3 , and/or R'_2 and/or R'_3 represent a $-(CH_2)_p-$ group, wherein p is an integer from 1 to 5.

41. (Currently Amended) Compounds according to claim 30, characterized in that R_2 and R_3 and/or R'_2 and R'_3 form a same substituent and form together with R_1 or respectively R'_1 a bis-oxadiazole of formula (VIII)[[.]]



~~in which R_a is as defined above.~~

Claims 42-52. (Cancelled)

53. (Previously Presented) Pharmaceutical compositions, characterized in that they contain an effective quantity of at least one compound as defined in claim 29 in association with an inert pharmaceutical vehicle.

54. (Previously Presented) Pharmaceutical compositions according to claim 53, characterized in that they can be administered by oral route, by injectable route, or also by rectal route.

55. (Currently Amended) Pharmaceutical ~~[[C]]~~ compositions according to claim 53 for the treatment of infectious diseases, in particular malaria.

Claims 56-57. (Cancelled)